Bone and renal safety profile at 72 weeks after switching to tenofovir alafenamide in chronic hepatitis B patients.

ABSTRACT:

Background and aim

Tenofovir disoproxil fumarate (TDF) has been efficacious in treating chronic hepatitis B (CHB), but long-term use is accompanied by a decline in renal function and bone mineral density (BMD). Tenofovir alefanamide (TAF) is a prodrug of tenofovir, with similar efficacy in CHB but with fewer side effects than TDF. Recent studies on patients who underwent the switch from TDF to TAF have shown improved bone and renal profiles from 24 to 48 weeks of follow-up.

Methods

This study provides follow-up at 72 weeks in a real-world cohort of 61 Asian CHB patients who were switched from TDF to TAF. All patients had been treated with TDF for at least 12 months with hepatitis B virus DNA <21 IU/mL prior to switch.

Results

Improvements in proximal tubular function,

SUBMITTER: Lee BT 

PROVIDER: S-EPMC7857293 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature